ICON Public Limited (NASDAQ:ICLR) Receives $289.10 Average PT from Analysts

Shares of ICON Public Limited (NASDAQ:ICLR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $289.10.

ICLR has been the topic of several research analyst reports. Baird R W lowered ICON Public from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 24th. StockNews.com cut shares of ICON Public from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Truist Financial reissued a "buy" rating and issued a $284.00 price objective (down previously from $295.00) on shares of ICON Public in a research report on Wednesday, December 18th. JPMorgan Chase & Co. reduced their target price on shares of ICON Public from $375.00 to $280.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Finally, Barclays lowered their price target on ICON Public from $330.00 to $275.00 and set an "overweight" rating for the company in a report on Friday, October 25th.

Hedge Funds Weigh In On ICON Public

A number of institutional investors have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC bought a new position in shares of ICON Public during the second quarter worth about $54,000. EverSource Wealth Advisors LLC lifted its holdings in ICON Public by 39.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company's stock worth $129,000 after buying an additional 111 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company's stock worth $147,000 after acquiring an additional 96 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company's stock valued at $172,000 after acquiring an additional 151 shares during the last quarter. Finally, Crestwood Advisors Group LLC acquired a new stake in shares of ICON Public during the 2nd quarter valued at approximately $288,000. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Trading Up 1.4 %

Shares of NASDAQ ICLR traded up $2.92 during midday trading on Thursday, reaching $212.63. 537,903 shares of the stock were exchanged, compared to its average volume of 755,818. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a market capitalization of $17.54 billion, a P/E ratio of 23.70, a P/E/G ratio of 1.54 and a beta of 1.21. The stock has a 50 day moving average price of $212.42 and a 200-day moving average price of $276.66. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to analysts' expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.10 EPS. Equities research analysts expect that ICON Public will post 13.42 earnings per share for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.